|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wednesday
Biogen Idec reported positive Phase II data from its product BG-12, which could potentially become the first oral therapy for the treatment of multiple sclerosis. ...."Genentech also announced positive top-line Phase II data from its product Rituxan in multiple sclerosis (MS), suggesting the drug could play a prominent role in future MS-therapy. Rituxan is already a multi-billion dollar product approved for the treatment of Non-Hodgkins lymphoma and rheumatoid arthritis."
|